Biochemical Characterization of Human Prolyl Hydroxylase Domain Protein 2 Variants Associated with Erythrocytosis
Melissa B. Pappalardi(GlaxoSmithKline (United States)), Lusong Luo(Beijing Biocytogen (China)), John D. Martin(Harvard University), Huizhen Zhao(University of Pennsylvania), Benjamin J. Schwartz(University of California, Los Angeles), Leng A. Lor(South College), Thau Ho(GlaxoSmithKline (United States)), Robert A. Copeland(Unknown), Peter J. Tummino(Intarcia Therapeutics (United States)), Kevin J. Duffy(GlaxoSmithKline (United States)), Yong Jiang(GlaxoSmithKline (United States)), Richard R. Gontarek(South College), Matthew Burns(GlaxoSmithKline (United States)), Sharon Sweitzer(GlaxoSmithKline (United States))
Cited by 23
Related Papers
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
|Journal of Biological Chemistry|1998|3k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848